
Hoth Therapeutics (NASDAQ: HOTH) to host KOL Event Spotlighting HT-001, Novel Therapy
Developed to address EGFR inhibitor-induced skin toxicities in cancer patients NEW YORK, June 23, 2025— Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event […]